Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kuros Biosciences ( (CH:KURN) ) has shared an update.
Kuros Biosciences reported a 78% increase in total medical device sales for the first half of 2025, achieving its first-ever operating profit. The company has seen substantial growth in its MagnetOs product line, supported by strategic partnerships, FDA clearances, and international market expansion. Kuros is well-positioned for continued growth, with expectations of robust sales increases and further market penetration, particularly in the U.S. and emerging markets.
The most recent analyst rating on (CH:KURN) stock is a Buy with a CHF32.50 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
More about Kuros Biosciences
Kuros Biosciences is a leader in next-generation bone healing technologies, focusing on medical devices that enhance bone healing processes. The company is primarily involved in the spine and extremity segments, with a significant market presence in the U.S. and expanding globally.
Average Trading Volume: 215,236
Technical Sentiment Signal: Buy
Current Market Cap: CHF970.7M
Find detailed analytics on KURN stock on TipRanks’ Stock Analysis page.